Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL964 (Antabuse, Disulfiram, Disulfirame, Esperal, NSC-25953, ORA-102, ORA102) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
A3 receptor/Adenosine A3 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL256] [GtoPdb: 21] [UniProtKB: P0DMS8] | ||||||||
ChEMBL | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | B | 6.7 | pKi | 201 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | B | 6.45 | pIC50 | 356 | nM | IC50 | DrugMatrix in vitro pharmacology data |
aldehyde dehydrogenase 2 family member/Aldehyde dehydrogenase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1935] [GtoPdb: 2595] [UniProtKB: P05091] | ||||||||
ChEMBL | Inhibition of ALDH2 (unknown origin) | B | 5.47 | pIC50 | 3400 | nM | IC50 | Bioorg Med Chem Lett (2021) 40: 127958-127958 [PMID:33744437] |
aldehyde dehydrogenase 2 family member/Aldehyde dehydrogenase in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2812] [GtoPdb: 2595] [UniProtKB: P11884] | ||||||||
ChEMBL | Inhibition of recombinant rat ALDH activity in liver mitochondria | B | 4.4 | pIC50 | 39810.72 | nM | IC50 | J Med Chem (2009) 52: 7310-7314 [PMID:19883085] |
GtoPdb | - | - | 4.44 | pIC50 | 36400 | nM | IC50 | Biochem Pharmacol (2000) 60: 947-53 [PMID:10974203] |
Aldehyde dehydrogenase 1A1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3577] [UniProtKB: P00352] | ||||||||
ChEMBL | Inhibition of ALDH1A1 (unknown origin) | B | 6.89 | pIC50 | 130 | nM | IC50 | Bioorg Med Chem Lett (2021) 40: 127958-127958 [PMID:33744437] |
α2A-adrenoceptor/Alpha-2a adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1867] [GtoPdb: 25] [UniProtKB: P08913] | ||||||||
ChEMBL | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | B | 5.74 | pKi | 1839 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | B | 5.31 | pIC50 | 4904 | nM | IC50 | DrugMatrix in vitro pharmacology data |
α2B-adrenoceptor/Alpha-2b adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1942] [GtoPdb: 26] [UniProtKB: P18089] | ||||||||
ChEMBL | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | B | 5.83 | pKi | 1469 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | B | 5.49 | pIC50 | 3218 | nM | IC50 | DrugMatrix in vitro pharmacology data |
Arachidonate 15-lipoxygenase in Rabbit (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4358] [UniProtKB: P12530] | ||||||||
ChEMBL | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | B | 4.79 | pIC50 | 16066 | nM | IC50 | DrugMatrix in vitro pharmacology data |
Carbamate kinase in Giardia intestinalis (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4802003] [UniProtKB: O97438] | ||||||||
ChEMBL | Inhibition of Giardia lamblia carbamate Kinase preincubated for 15 mins followed by ADP and carbamate phosphate addition and measured after 20 mins by ATPLite reagent based luminescence assay | B | 6.22 | pIC50 | 600 | nM | IC50 | J Med Chem (2020) 63: 13330-13354 [PMID:32869995] |
CCR2/C-C chemokine receptor type 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4015] [GtoPdb: 59] [UniProtKB: P41597] | ||||||||
ChEMBL | DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) | B | 6.02 | pKi | 954 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) | B | 5.61 | pIC50 | 2468 | nM | IC50 | DrugMatrix in vitro pharmacology data |
CCR4/C-C chemokine receptor type 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2414] [GtoPdb: 61] [UniProtKB: P51679] | ||||||||
ChEMBL | DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) | B | 5.36 | pKi | 4397 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) | B | 5.08 | pIC50 | 8395 | nM | IC50 | DrugMatrix in vitro pharmacology data |
CCR5/C-C chemokine receptor type 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL274] [GtoPdb: 62] [UniProtKB: P51681] | ||||||||
ChEMBL | DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) | B | 4.74 | pKi | 18284 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) | B | 4.63 | pIC50 | 23661 | nM | IC50 | DrugMatrix in vitro pharmacology data |
CYP1A2/Cytochrome P450 1A2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3356] [GtoPdb: 1319] [UniProtKB: P05177] | ||||||||
ChEMBL | DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | B | 5.4 | pIC50 | 4000 | nM | IC50 | DrugMatrix in vitro pharmacology data |
D-3-phosphoglycerate dehydrogenase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2311243] [UniProtKB: O43175] | ||||||||
ChEMBL | Inhibition of human PHGDH by fluorescence based analysis | B | 6.23 | pIC50 | 590 | nM | IC50 | Eur J Med Chem (2021) 217: 113379-113379 [PMID:33756126] |
D1 receptor/Dopamine D1 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2056] [GtoPdb: 214] [UniProtKB: P21728] | ||||||||
ChEMBL | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | B | 5.97 | pKi | 1079 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | B | 5.67 | pIC50 | 2158 | nM | IC50 | DrugMatrix in vitro pharmacology data |
D2 receptor/Dopamine D2 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL217] [GtoPdb: 215] [UniProtKB: P14416] | ||||||||
ChEMBL | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | B | 5.12 | pKi | 7673 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | B | 4.64 | pIC50 | 23018 | nM | IC50 | DrugMatrix in vitro pharmacology data |
D3 receptor/Dopamine D3 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL234] [GtoPdb: 216] [UniProtKB: P35462] | ||||||||
ChEMBL | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | B | 6.43 | pKi | 368 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | B | 5.96 | pIC50 | 1084 | nM | IC50 | DrugMatrix in vitro pharmacology data |
D4 receptor/Dopamine D4 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL219] [GtoPdb: 217] [UniProtKB: P21917] | ||||||||
ChEMBL | DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) | B | 5.96 | pKi | 1105 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) | B | 5.5 | pIC50 | 3150 | nM | IC50 | DrugMatrix in vitro pharmacology data |
DAT/Dopamine transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL238] [GtoPdb: 927] [UniProtKB: Q01959] | ||||||||
ChEMBL | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 5.43 | pKi | 3684 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 5.33 | pIC50 | 4637 | nM | IC50 | DrugMatrix in vitro pharmacology data |
Fructose-1,6-bisphosphatase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3975] [UniProtKB: P09467] | ||||||||
ChEMBL | Inhibition of human liver FBPase C179S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay | B | 5.72 | pIC50 | 1900 | nM | IC50 | J Med Chem (2020) 63: 6238-6247 [PMID:32375478] |
ChEMBL | Inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3) using FBP as substrate by malachite green dye based assay | B | 5.75 | pIC50 | 1780 | nM | IC50 | Eur J Med Chem (2020) 203: 112500-112500 [PMID:32711108] |
ChEMBL | Inhibition of human FBPase expressed Escherichia coli BL21 in by malachite green dye based spectrophotometry | B | 5.82 | pIC50 | 1500 | nM | IC50 | J Med Chem (2022) 65: 9126-9143 [PMID:35786925] |
ChEMBL | Inhibition of human liver FBPase C183S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay | B | 5.82 | pIC50 | 1500 | nM | IC50 | J Med Chem (2020) 63: 6238-6247 [PMID:32375478] |
ChEMBL | Inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay | B | 5.82 | pIC50 | 1500 | nM | IC50 | J Med Chem (2020) 63: 6238-6247 [PMID:32375478] |
ChEMBL | Inhibition of human liver FBPase C116S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay | B | 5.89 | pIC50 | 1300 | nM | IC50 | J Med Chem (2020) 63: 6238-6247 [PMID:32375478] |
ChEMBL | Inhibition of human liver FBPase C92S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay | B | 5.92 | pIC50 | 1200 | nM | IC50 | J Med Chem (2020) 63: 6238-6247 [PMID:32375478] |
ChEMBL | Inhibition of human liver FBPase C281S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay | B | 5.96 | pIC50 | 1100 | nM | IC50 | J Med Chem (2020) 63: 6238-6247 [PMID:32375478] |
ChEMBL | Inhibition of human liver FBPase C38S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay | B | 6.22 | pIC50 | 600 | nM | IC50 | J Med Chem (2020) 63: 6238-6247 [PMID:32375478] |
gasdermin D/Gasdermin-D in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523247] [GtoPdb: 3278] [UniProtKB: P57764] | ||||||||
ChEMBL | Inhibition of GSDMD in human monocyte/macrophages assessed as inhibition of pyroptosis in presence of Cu2+ | B | 6.4 | pIC50 | 400 | nM | IC50 | Medchemcomm (2019) 10: 660-667 [PMID:31191857] |
Gasdermin-D in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523446] [UniProtKB: Q9D8T2] | ||||||||
ChEMBL | Inhibition of GSDMD in mouse monocyte/macrophages assessed as inhibition of pyroptosis in presence of Cu2+ | B | 6.4 | pIC50 | 400 | nM | IC50 | Medchemcomm (2019) 10: 660-667 [PMID:31191857] |
euchromatic histone lysine methyltransferase 2/Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6032] [GtoPdb: 2652] [UniProtKB: Q96KQ7] | ||||||||
ChEMBL | Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measured after 60 mins by MALDI-TOF MS analysis | B | 6.22 | pIC50 | 600 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 1234-1238 [PMID:29519735] |
euchromatic histone lysine methyltransferase 1/Histone-lysine N-methyltransferase, H3 lysine-9 specific 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6031] [GtoPdb: 2651] [UniProtKB: Q9H9B1] | ||||||||
ChEMBL | Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measured after 60 mins by MALDI-TOF MS analysis | B | 5.8 | pIC50 | 1600 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 1234-1238 [PMID:29519735] |
CXCR2/Interleukin-8 receptor B in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2434] [GtoPdb: 69] [UniProtKB: P25025] | ||||||||
ChEMBL | DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) | B | 5.38 | pKi | 4209 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) | B | 5.22 | pIC50 | 6013 | nM | IC50 | DrugMatrix in vitro pharmacology data |
κ receptor/Kappa opioid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL237] [GtoPdb: 318] [UniProtKB: P41145] | ||||||||
ChEMBL | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 5.61 | pKi | 2441 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 5.21 | pIC50 | 6103 | nM | IC50 | DrugMatrix in vitro pharmacology data |
lysine demethylase 5A/Lysine-specific demethylase 5A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2424504] [GtoPdb: 2680] [UniProtKB: P29375] | ||||||||
ChEMBL | Inhibition of JARID1A PHD finger domain (unknown origin) | B | 5 | pIC50 | 10000 | nM | IC50 | Eur J Med Chem (2017) 136: 14-35 [PMID:28478342] |
lysyl oxidase/Lysyl oxidase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2249] [GtoPdb: 3097] [UniProtKB: P28300] | ||||||||
ChEMBL | Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | B | 6.49 | pIC50 | 320 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 3113-3118 [PMID:30098867] |
lysyl oxidase like 2/Lysyl oxidase homolog 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3714029] [GtoPdb: 2853] [UniProtKB: Q9Y4K0] | ||||||||
ChEMBL | Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | B | 6.82 | pIC50 | 150 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 3113-3118 [PMID:30098867] |
Lysyl oxidase homolog 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4105989] [UniProtKB: P58215] | ||||||||
ChEMBL | Inhibition of recombinant human LOXL3 expressed in CHO cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | B | 7.03 | pIC50 | 93 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 3113-3118 [PMID:30098867] |
Lysyl oxidase homolog 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4295926] [UniProtKB: Q96JB6] | ||||||||
ChEMBL | Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | B | 7.23 | pIC50 | 59 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 3113-3118 [PMID:30098867] |
mitogen-activated protein kinase 3/MAP kinase ERK1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3385] [GtoPdb: 1494] [UniProtKB: P27361] | ||||||||
ChEMBL | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) | B | 5.82 | pIC50 | 1510 | nM | IC50 | DrugMatrix in vitro pharmacology data |
Monoamine oxidase A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1951] [GtoPdb: 2489] [UniProtKB: P21397] | ||||||||
ChEMBL | DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) | B | 4.86 | pIC50 | 13734 | nM | IC50 | DrugMatrix in vitro pharmacology data |
monoacylglycerol lipase/Monoglyceride lipase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4191] [GtoPdb: 1399] [UniProtKB: Q99685] | ||||||||
ChEMBL | Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate by liquid scintillation counting | B | 5.9 | pIC50 | 1258.93 | nM | IC50 | J Med Chem (2009) 52: 7310-7314 [PMID:19883085] |
ChEMBL | Inhibition of recombinant human N-terminal His6-tagged and C-terminal Strep-tagged MAGL expressed in Escherichia coli Rosetta using [3H]2-OG as substrate after 10 mins by liquid scintillation counting method | B | 6.44 | pIC50 | 360 | nM | IC50 | J Med Chem (2017) 60: 4-46 [PMID:27766867] |
μ receptor/Mu opioid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL233] [GtoPdb: 319] [UniProtKB: P35372] | ||||||||
ChEMBL | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 5.85 | pKi | 1425 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | B | 5.45 | pIC50 | 3511 | nM | IC50 | DrugMatrix in vitro pharmacology data |
NLRP3/NACHT, LRR and PYD domains-containing protein 3 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3779755] [GtoPdb: 1770] [UniProtKB: Q8R4B8] | ||||||||
ChEMBL | Inhibition of NLRP3 in mouse J774A.1 cells infected with FLA-ST assessed as inhibition of LPS- induced IL-1beta production by ELISA | B | 5.52 | pIC50 | 3000 | nM | IC50 | Eur J Med Chem (2021) 219: 113417-113417 [PMID:33845232] |
NET/Norepinephrine transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL222] [GtoPdb: 926] [UniProtKB: P23975] | ||||||||
ChEMBL | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 4.16 | pKi | 69812 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | B | 4.15 | pIC50 | 70370 | nM | IC50 | DrugMatrix in vitro pharmacology data |
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
ChEMBL | Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay | F | 5 | pIC50 | 10000 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
ChEMBL | Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay | F | 5.2 | pIC50 | 6309.57 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
ChEMBL | Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay | F | 5.4 | pIC50 | 3981.07 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
ChEMBL | Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay | F | 5.5 | pIC50 | 3162.28 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
ChEMBL | Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay | F | 5.6 | pIC50 | 2511.89 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
Replicase polyprotein 1ab in Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (Betacoronavirus England 1) (Humancoronavirus EMC) (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4295557] [UniProtKB: K9N7C7] | ||||||||
ChEMBL | MERS_3CL Pro protease inhibition IC50 by FRET kind of response from peptide substrate | F | 4.57 | pIC50 | 26800 | nM | IC50 | Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen |
ChEMBL | Inhibition of recombinant MERS-CoV PL protease using Ub-AFC incubated for 3 mins by fluorescence based analysis | B | 4.84 | pIC50 | 14600 | nM | IC50 | Bioorg Med Chem (2020) 28: 115757-115757 [PMID:32992245] |
CoV Replicase polyprotein 1ab/CoV RNA-dependent RNA polymerase/CoV Non-structural protein 15/CoV Non-structural protein 13/Replicase polyprotein 1ab in Severe acute respiratory syndrome coronavirus 2 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523582] [GtoPdb: 3125, 3139, 3206, 3261] [UniProtKB: P0DTD1] | ||||||||
ChEMBL | Inhibition of recombinant SARS CoV-2 PL protease using Ub-AFC incubated for 3 mins by fluorescence based analysis | B | 4.62 | pIC50 | 24100 | nM | IC50 | Bioorg Med Chem (2020) 28: 115757-115757 [PMID:32992245] |
ChEMBL | Inhibition of SARS-CoV-2 MPro | B | 5.03 | pIC50 | 9354.06 | nM | IC50 | Bioorg Med Chem (2021) 29: 115860-115860 [PMID:33191083] |
ChEMBL | Inhibition of SARS-C0V-2 main protease | B | 5.03 | pIC50 | 9350 | nM | IC50 | Eur J Med Chem (2023) 257: 115491-115491 [PMID:37244162] |
ChEMBL | Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) using Mca-AVLQ SGFR-K(Dnp)K as substrate by EnVision multimode plate reader analysis | B | 5.03 | pIC50 | 9350 | nM | IC50 | Bioorg Med Chem (2021) 29: 115860-115860 [PMID:33191083] |
ChEMBL | Inhibition of SARS-COV2 main protease using Mca-AVLQ-SGFR-K as substrate by Fluorescence microplate reader assay | B | 5.03 | pIC50 | 9350 | nM | IC50 | Eur J Med Chem (2021) 213: 113157-113157 [PMID:33486200] |
ChEMBL | Inhibition of SARS-CoV-2 main protease | B | 5.03 | pIC50 | 9350 | nM | IC50 | Eur J Med Chem (2020) 201: 112559-112559 [PMID:32563814] |
ChEMBL | Inhibition of C-terminal His 6 tagged SARS CoV-2 main protease transfected in Escherichia coli BL21 (DE3) | B | 5.05 | pIC50 | 9000 | nM | IC50 | ACS Med Chem Lett (2023) 14: 1610-1614 [PMID:38116411] |
ChEMBL | Inhibition of SARS-CoV-2 papain-like protease expressed in Escherichia coli BL21(DE3) using Dabcy-FTLKGGAPTKVTE-Edans-NH2 as substrate by multilabel plate reader analysis | B | 5.12 | pIC50 | 7520 | nM | IC50 | J Med Chem (2022) 65: 7561-7580 [PMID:35620927] |
ChEMBL | Inhibition of SARS-CoV 3CL protease using Dabcyl-KNSTLQSGLRKE-Edan as substrate incubated for 30 mins and measured by FRET assay | B | 5.17 | pIC50 | 6720 | nM | IC50 | Eur J Med Chem (2022) 228: 114030-114030 [PMID:34883292] |
ChEMBL | Inhibition of SARS-CoV-2 3CL protease using Dabcyl-KNSTLQSGLRKE-Edan as substrate incubated for 30 mins and measured by FRET assay | B | 5.98 | pIC50 | 1040 | nM | IC50 | Eur J Med Chem (2022) 228: 114030-114030 [PMID:34883292] |
ChEMBL | Inhibition of recombinant SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) using Mca-AVLQSGFR-K(Dnp)K as substrate by fluorescence based assay | B | 6.17 | pIC50 | 670 | nM | IC50 | RSC Med Chem (2021) 12: 1026-1036 [PMID:34355175] |
ChEMBL | SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate | F | 6.66 | pIC50 | 220 | nM | IC50 | Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen |
5-HT1B receptor/Serotonin 1b (5-HT1b) receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3459] [GtoPdb: 2] [UniProtKB: P28564] | ||||||||
ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) | B | 5.67 | pKi | 2145 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) | B | 5.33 | pIC50 | 4720 | nM | IC50 | DrugMatrix in vitro pharmacology data |
5-HT2B receptor/Serotonin 2b (5-HT2b) receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1833] [GtoPdb: 7] [UniProtKB: P41595] | ||||||||
ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 4.66 | pKi | 21984 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 4.46 | pIC50 | 34547 | nM | IC50 | DrugMatrix in vitro pharmacology data |
5-HT6 receptor/Serotonin 6 (5-HT6) receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3371] [GtoPdb: 11] [UniProtKB: P50406] | ||||||||
ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 5.13 | pKi | 7429 | nM | Ki | DrugMatrix in vitro pharmacology data |
ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 4.8 | pIC50 | 16001 | nM | IC50 | DrugMatrix in vitro pharmacology data |
TRPA1/Transient receptor potential cation channel subfamily A member 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6007] [GtoPdb: 485] [UniProtKB: O75762] | ||||||||
ChEMBL | Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels | F | 5.52 | pEC50 | 3000 | nM | EC50 | J Med Chem (2010) 53: 5085-5107 [PMID:20356305] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]